ABSTRACT
Glaucoma is a leading cause of irreversible blindness worldwide, with early diagnosis often hindered by subtle symptomatology and the lack of comprehensive screening programs. In this study, we introduce a robust deep learning framework that leverages supervised pre-training with clinically relevant intermediate indicators, most notably the vertical cup-to-disc ratio (VCDR), to enhance glaucoma detection from color fundus images. Utilizing the expansive AIROGS dataset for pre-training, our multi-task learning strategy simultaneously addresses categorical diagnostic classification and VCDR regression. We evaluated three architectures, ResNet-18, DINOv2, and RETFound across multiple international cohorts, including DRISHTI, G1020, ORIGA, PAPILA, REFUGE1, and ACRIMA. Compared to out-of-domain pre-training or self-supervised pre-training, supervised pre-training achieved the best average performances on all of ResNet-18 (average AUROC = 0.857), DINOv2 (average AUROC = 0.788), and RETFound (average AUROC = 0.839). The best model is the ResNet-18 pre-trained with AIROGS diagnostic features, achieving the highest AUROC of 0.930 on the G1020 dataset, and an average AUROC of 0.857 across all datasets. These results underscore the superiority of incorporating domain-specific clinical labels to guide feature extraction, thereby improving model performance, and generalizability for glaucoma detection. Our findings advocate for the integration of supervised pre-training strategies into glaucoma detection model development, with significant potential to improve model performance and ultimately improve patient outcomes with decreased undiagnosed rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Saudi Data and Artificial Intelligence Authority (SDAIA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The datasets used in this study are all publicly available. The AIROGS dataset can be accessed through https://airogs.grand-challenge.org/. The SMDG-19 dataset can be accessed through https://www.kaggle.com/datasets/deathtrooper/multichannel-glaucoma-benchmark-dataset. The ACRIMA dataset can be accessed through https://www.kaggle.com/datasets/toaharahmanratul/acrima-dataset.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript has been revised to add Dr. Adi Mohammed Al Owaifeer, as a co-author due to his contributions to the data collection and processing work.
